AURA BIOSCIENCES INC (AURA)
Sector: Health Care
2026 Annual Meeting Analysis
AURA BIOSCIENCES INC · Meeting: June 11, 2026
Directors FOR
1
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Against Analysis
Mr. Johnson has served on the board since January 2021, giving him meaningful tenure over the full 3-year underperformance period; Aura's stock has declined 19% over three years while the biotech benchmark XBI (SPDR S&P Biotech ETF) gained 68.4%, a gap of -87.4 percentage points that far exceeds the 30-percentage-point threshold required to trigger a vote against, and the 5-year record (Aura -52.4% vs. XBI) does not provide a mitigating longer track record of adequate performance, so the against vote is confirmed.
For Analysis
Ms. Bitetti joined the board in March 2025, which is less than 24 months before the June 2026 meeting, so she is exempt from the TSR underperformance trigger under the policy's new-director exemption; she brings deep oncology commercialization experience from Takeda and Bristol Myers Squibb that is highly relevant to Aura's clinical-stage oncology pipeline, and no other disqualifying factors (overboarding, attendance issues, independence concerns, or familial relationships) were identified.
Of the two Class II director nominees, Teresa Marie Bitetti receives a FOR vote because she joined the board within the last 24 months and is exempt from the TSR trigger, while David Johnson receives an AGAINST vote because his tenure covers the full 3-year period during which Aura's stock underperformed XBI by 87.4 percentage points — well above the 30-point threshold — and the 5-year record does not provide a mitigating track record.
Say on Pay
✓ FORCEO
Elisabet de los Pinos, Ph.D.
Total Comp
$3,956,167
Prior Support
N/A
Aura is an emerging growth company and is not required to hold a Say on Pay vote, so this proposal does not appear on the 2026 ballot and no prior-year support figure exists; however, reviewing the CEO's disclosed 2025 total compensation of approximately $3.96 million against the benchmark for a biotech CEO at a sub-$500 million market cap company, the pay level appears broadly reasonable and the pay mix is predominantly variable (salary of $645,483 represents roughly 16% of total compensation, with the remainder in equity awards and a performance bonus), which meets the policy's requirement that fixed pay not dominate total compensation. The incentive structure includes a corporate goal achievement assessment (80% of goals met in 2025) and a functioning clawback policy, and no significant governance red flags were identified in the compensation program.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
10 yrs
Audit Fees
$867,768
Non-Audit Fees
$272,585
Ernst & Young has audited Aura since 2016, giving it approximately 10 years of tenure — well below the 25-year threshold that would raise independence concerns; the non-audit fees (tax services of $272,585) represent about 31% of audit fees ($867,768), which is comfortably below the 50% threshold; no material restatements were disclosed; and Ernst & Young is a Big 4 firm appropriate for a company of Aura's size and complexity.
Overall Assessment
The 2026 Aura Biosciences annual meeting presents two proposals: director elections and auditor ratification. The auditor ratification receives a FOR vote with no concerns, but one of the two director nominees — board chairman David Johnson, who has served since 2021 — receives an AGAINST vote due to severe stock underperformance versus the biotech benchmark XBI (SPDR S&P Biotech ETF) over his tenure, while new director Teresa Marie Bitetti receives a FOR vote as she is exempt from the TSR trigger having joined the board less than 24 months ago.